Work

Supplementary Figure S1 from Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma

Year: 2023

Type: supplementary-materials

Abstract: Figure S1. Individual and mean AUC0-24 ({plus minus} standard deviation) in patients with solid tumors (37) (n = 14) or lymphoma (n = 9) on cycle 1, day 28 after treatment with pilaralisib (SAR245408) 600 mg capsules once daily.

DOI: 10.1158/1078-0432.22458534

Authors: Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Siddha N. Kasar, Joanne Lager, Jason Jiang, Coumaran Egile, Farrukh T. Awan

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361918070

Cites:

Cited by:

Related to: 10